Market capitalization | $181.19m |
Enterprise Value | $97.92m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.23 |
P/S ratio (TTM) P/S ratio | 2.28 |
P/B ratio (TTM) P/B ratio | 1.89 |
Revenue growth (TTM) Revenue growth | -3.99% |
Revenue (TTM) Revenue | $79.54m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
8 Analysts have issued a Sight Sciences Inc forecast:
8 Analysts have issued a Sight Sciences Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 80 80 |
4%
4%
|
|
Gross Profit | 68 68 |
3%
3%
|
|
EBITDA | -49 -49 |
21%
21%
|
EBIT (Operating Income) EBIT | -50 -50 |
21%
21%
|
Net Profit | -50 -50 |
18%
18%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Sight Sciences, Inc. is a medical device company, which engages in the provision of glaucoma implants for treatment of irreversible blindness. It also develops pharmaceuticals, drug delivery systems, and diagnostics for the treatment of ophthalmic conditions. The firms products include viscosurgical system and trabeculotomy instrument. It operates through the Surgical Glaucoma and Dry Eye segments. The Surgical Glaucoma segment includes OMNI Surgical System for use in minimally invasive glaucoma procedures. The Dry Eye segment offers TearCare System and related components. The company was founded by Paul Badawi and David Y. Badawi in 2011 and is headquartered in Menlo Park, CA.
Head office | United States |
CEO | Paul Badawi |
Employees | 214 |
Founded | 2011 |
Website | www.sightsciences.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.